CG Oncology CGON EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from CG Oncology’s reported figures.
The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about CG Oncology's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CG Oncology's EBITDA?
- CG Oncology (CGON) reported EBITDA of -$65.55M in Q1 2026.
- How has CG Oncology's EBITDA changed year-over-year?
- CG Oncology's EBITDA decreased by 55.4% year-over-year, from -$42.18M to -$65.55M.
- What is the long-term trend for CG Oncology's EBITDA?
- Over 2 years (2023 to 2025), CG Oncology's EBITDA has grown at a 84.8% compound annual growth rate (CAGR), from -$55.43M to -$189.33M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.